Navigation Links
Enterome Announces Collaboration with Johnson & Johnson Innovation Focused on the Discovery of Novel Targets and Therapeutics for Crohn's Disease
Date:1/7/2016

PARIS and BOSTON, January 7, 2016 /PRNewswire/ --

Enterome Bioscience SA ("Enterome"), a pioneer in the development of therapeutic solutions based on the gut microbiome, announces that it has entered into a collaborative research agreement with Janssen Biotech, Inc. (Janssen Biotech), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the French National Institute for Agriculture Research (INRA).

The agreement, facilitated by Johnson & Johnson Innovation, is focused on the discovery of novel targets and bioactive molecules from the gut microbiome for the potential development of therapeutic solutions to Crohn's disease. 

Enterome has already identified bacterial strains, genes and products with immunomodulatory and anti-inflammatory properties by combining its own advanced proprietary metagenomics tools and screening technologies. The collaboration aims to advance the characterization and therapeutic validation of these bacterial products, increase knowledge of the regulation of immunity and gut homeostasis, and potentially lead to the development of new therapeutic solutions for Crohn's disease.

Under the terms of the agreement, Enterome is eligible to receive an upfront payment plus R&D funding from Janssen. Janssen receives an option to take an exclusive license to further develop and commercialize promising candidates that may arise from the collaboration. The Janssen Human Microbiome Institute will also join the collaboration to help accelerate the translation of microbiome science into therapeutic solutions in the area of Crohn's disease.

The collaboration is based on initial findings by INRA showing that some commensal (symbiotic) bacteria elicit anti-inflammatory effects in the human gut.  

Pierre Belichard, CEO of Enterome commented, "Enterome is proud of its leading position in discovering and developing microbiome-derived therapeutics for Crohn's disease, and we look forward to advancing through collaborations that continue to reflect positively on our strong recognition from the pharmaceutical industry."

About Enterome 

Enterome is pioneering the development of novel drugs and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic diseases.

Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs.

The Company was established in 2012 in Paris, France to develop the discoveries made by the INRA metagenomic platform. The Company has raised a total of €17.5 million from leading venture capital investors (Seventure Partners, Lundbeckfond Ventures & Omnes Capital) and two strategic investors (Shire & INRA transfer).

Additional information about Enterome is available through its website:  http://www.enterome.com


'/>"/>
SOURCE Enterome Bioscience
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call
2. EnteroMedics to Participate in Canaccord Genuity 34th Annual Growth Conference
3. EnteroMedics Reports Second Quarter 2014 Financial Results
4. Health Care Equipment Equities under the Scanner - Medtronic, Abbott Laboratories, Stryker, Zeltiq Aesthetics, and EnteroMedics
5. Treatment of Type 2 Diabetes Mellitus added to EnteroMedics CE Mark for Obesity
6. EnteroMedics to Host Fourth Quarter 2014 Financial Results and Commercialization Update Conference Call
7. EnteroMedics Reports Fourth Quarter 2014 Financial Results
8. EnteroMedics to Present at Upcoming Investor Conferences
9. EnteroMedics Announces Partnership with American HealthCare Lending to Support Patient Access and Enhance Affordability of vBloc Therapy
10. EnteroMedics Announces Update on vBloc Therapy Trained Centers and Physicians
11. EnteroMedics Reports First Quarter 2015 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
(Date:9/12/2017)... , Sept. 12, 2017  Consumer reviews on the independent review ... as the number one company for hearing aids, ranking it higher ... other brands. ... Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high performance, state-of-the-art, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest ... its plans to open a flagship location in Covington, LA at 401 N. U.S. ... Go store next to Office Depot in the Holiday Square shopping center. Its location ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
Breaking Medicine News(10 mins):